Page last updated: 2024-10-27

fluoxetine and Alcoholism

fluoxetine has been researched along with Alcoholism in 51 studies

Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.

Alcoholism: A primary, chronic disease with genetic, psychosocial, and environmental factors influencing its development and manifestations. The disease is often progressive and fatal. It is characterized by impaired control over drinking, preoccupation with the drug alcohol, use of alcohol despite adverse consequences, and distortions in thinking, most notably denial. Each of these symptoms may be continuous or periodic. (Morse & Flavin for the Joint Commission of the National Council on Alcoholism and Drug Dependence and the American Society of Addiction Medicine to Study the Definition and Criteria for the Diagnosis of Alcoholism: in JAMA 1992;268:1012-4)

Research Excerpts

ExcerptRelevanceReference
"The drugs relieve depressive disorders: fluvoxamine by the 7th day of treatment, sertraline, paroxetine, citalopram by the 14th day, fluoxetine by the 30th day of therapy."9.41[Fluvoxamine in the treatment of depressive disorders in alcohol dependence: results of randomized open-label comparative study]. ( Komarov, SD; Severtsev, VV; Vdovin, AS; Vinnikova, MA, 2021)
" In addition, hypericum extracts, as well as standard antidepressants such as the tricyclic, impramine, and the selective serotonin reuptake inhibitor, fluoxetine, have been reported to be of therapeutic benefit in the treatment of alcoholism, as these compounds may reduce alcohol craving and/or intake in particular subgroups of patients."7.70Comparison of hypericum extracts with imipramine and fluoxetine in animal models of depression and alcoholism. ( de Beun, R; De Vry, J; Jentzsch, KR; Maurel, S; Schreiber, R, 1999)
"The drugs relieve depressive disorders: fluvoxamine by the 7th day of treatment, sertraline, paroxetine, citalopram by the 14th day, fluoxetine by the 30th day of therapy."5.41[Fluvoxamine in the treatment of depressive disorders in alcohol dependence: results of randomized open-label comparative study]. ( Komarov, SD; Severtsev, VV; Vdovin, AS; Vinnikova, MA, 2021)
"The selective serotonergic agonist fluoxetine has demonstrated efficacy in the treatment of depression and has possible efficacy in the treatment of nondepressed and depressed alcoholics."5.08Preliminary report: double-blind, placebo-controlled study of fluoxetine in depressed alcoholics. ( Black, A; Cornelius, JR; Cornelius, MD; Ehler, JG; Jarrett, PJ; Levin, RL; Mann, JJ; Perel, JM; Salloum, IM, 1995)
" In this study, 25 smokers with DSM-III-R diagnoses of both major depressive disorder and alcohol dependence were randomized to fluoxetine or placebo in a 12-week, double-blind, parallel group trial."5.08Double-blind fluoxetine in depressed alcoholic smokers. ( Black, A; Cornelius, JR; Cornelius, MD; Ehler, JG; Jarrett, PJ; Perel, JM; Salloum, IM; Thase, ME, 1997)
"The selective serotonergic medication fluoxetine has demonstrated efficacy in the treatment of major depression and has suggested efficacy in the treatment of alcoholism."5.08Fluoxetine in depressed alcoholics. A double-blind, placebo-controlled trial. ( Black, A; Cornelius, JR; Cornelius, MD; Ehler, JG; Jarrett, PJ; Perel, JM; Salloum, IM; Thase, ME, 1997)
" In this study, 17 patients with DSM-III-R diagnoses of major depressive disorder, alcohol dependence, and cocaine abuse were included along with 34 non-cocaine-abusing depressed alcoholics in a pharmacotherapy trial involving the SSRI antidepressant fluoxetine."5.08Fluoxetine versus placebo in depressed alcoholic cocaine abusers. ( Cornelius, JR; Daley, DC; Haskett, RF; Jones-Barlock, A; Perel, JM; Salloum, IM; Thase, ME; Upsher, C, 1998)
"The selective serotonergic agonist fluoxetine has demonstrated efficacy in the treatment of depression and has suggested efficacy in the treatment of alcoholism."5.07Fluoxetine trial in suicidal depressed alcoholics. ( Cornelius, JR; Cornelius, MD; Ehler, JG; Mann, JJ; Perel, JM; Salloum, IM; Thase, ME, 1993)
"The effects of fluoxetine, a relatively selective long-acting serotonin uptake inhibitor, on the consumption of alcoholic and nonalcoholic drinks, cigarette smoking, and body weight were assessed in 29 men who were early stage problem drinkers."5.06Fluoxetine differentially alters alcohol intake and other consummatory behaviors in problem drinkers. ( Kadlec, KE; Naranjo, CA; Sanhueza, P; Sellers, EM; Woodley-Remus, D, 1990)
" In addition, hypericum extracts, as well as standard antidepressants such as the tricyclic, impramine, and the selective serotonin reuptake inhibitor, fluoxetine, have been reported to be of therapeutic benefit in the treatment of alcoholism, as these compounds may reduce alcohol craving and/or intake in particular subgroups of patients."3.70Comparison of hypericum extracts with imipramine and fluoxetine in animal models of depression and alcoholism. ( de Beun, R; De Vry, J; Jentzsch, KR; Maurel, S; Schreiber, R, 1999)
"Naltrexone (NTX) and fluoxetine (FLU) are useful for treating alcoholism and depression, respectively."3.69Combination of naltrexone and fluoxetine on rats' propensity to take alcoholic beverage. ( Cavallaro, CA; Chattophadyay, S; Gardell, LR; Hubbell, CL; Reid, LD; Whalen, CA, 1997)
"Fluoxetine-treated subjects who remained sober at 12 weeks reported a significant decrease in mean subjective alcohol craving scores from 2."2.68A placebo-controlled, double-blind study of fluoxetine in severe alcohol dependence: adjunctive pharmacotherapy during and after inpatient treatment. ( Kabel, DI; Petty, F, 1996)
"bromocriptine)."2.39Neurobehavioural basis for the pharmacotherapy of alcoholism: current and future directions. ( Anton, RF, 1996)
"Our study included 101 patients with major depressive disorder and alcohol use disorder (average age: 41."1.62Impact of CYP2D6 Polymorphism on Equilibrium Concentration of Fluoxetine in Patients Diagnosed With Major Depressive Disorder and Comorbid Alcohol Use Disorders. ( Bryun, EA; Grishina, EA; Pankratenko, EP; Petukhov, AE; Ryzhikova, KA; Shipitsyn, VV; Skryabin, VY; Sychev, DA; Torrado, MV; Zastrozhin, MS, 2021)
"fluoxetine treatment induced a long-lasting increase in alcohol consumption during relapse, an effect that was not observed in the case of bupropion treatment."1.51Bupropion, a possible antidepressant without negative effects on alcohol relapse. ( Alen, F; Antón, M; Arco, R; Ballesta, A; de Fonseca, FR; de Heras, RG; Nogueira-Arjona, R; Orio, L; Pavón, FJ; Ramírez-López, M; Romero-Sanchiz, P; Serrano, A; Suárez, J; Vargas, A, 2019)
"Aripiprazole (ARI) is an atypical antipsychotic drug, which has also been shown to have a beneficial effect on cognitive function."1.40Evaluation of antidepressant and memory-improving efficacy of aripiprazole and fluoxetine in alcohol-preferring rats. ( Burda-Malarz, K; Czubak, A; Jędrzejewski, L; Kus, K; Nowakowska, E; Ratajczak, P; Sadowski, C, 2014)
"Milnacipran was also tested for relapse after protracted abstinence and on ethanol-induced (1."1.37Fluoxetine, desipramine, and the dual antidepressant milnacipran reduce alcohol self-administration and/or relapse in dependent rats. ( Alaux-Cantin, S; André, E; Houchi, H; Legastelois, R; Naassila, M; Pierrefiche, O; Simon O'Brien, E; Vilpoux, C, 2011)
"Buspirone was without important effects on the high alcohol preferring rats."1.29Effects of various serotonergic agents on alcohol intake and alcohol preference in Wistar rats selected at two different levels of alcohol preference. ( Meert, TF, 1993)

Research

Studies (51)

TimeframeStudies, this research(%)All Research%
pre-19901 (1.96)18.7374
1990's29 (56.86)18.2507
2000's10 (19.61)29.6817
2010's8 (15.69)24.3611
2020's3 (5.88)2.80

Authors

AuthorsStudies
Zastrozhin, MS1
Skryabin, VY1
Petukhov, AE1
Pankratenko, EP1
Grishina, EA1
Ryzhikova, KA1
Torrado, MV1
Shipitsyn, VV1
Bryun, EA1
Sychev, DA1
Vinnikova, MA1
Severtsev, VV1
Komarov, SD1
Vdovin, AS1
Ballesta, A2
Orio, L1
Arco, R2
Vargas, A1
Romero-Sanchiz, P1
Nogueira-Arjona, R1
de Heras, RG1
Antón, M1
Ramírez-López, M1
Serrano, A1
Pavón, FJ1
de Fonseca, FR1
Suárez, J2
Alen, F2
Khom, S1
Natividad, LA1
Varodayan, FP1
Patel, RR1
Kirson, D1
Bajo, M1
Rubio, L1
Martin-Fardon, R1
Rodríguez de Fonseca, F1
Roberto, M1
Burda-Malarz, K2
Kus, K2
Ratajczak, P2
Czubak, A2
Hardyk, S1
Nowakowska, E2
Jędrzejewski, L1
Sadowski, C1
Aragones, JM1
Blanch, CE1
Guillen-Font, A1
Escote-Llobet, S1
Hu, J1
Xia, Y1
Wu, Z1
Liu, L1
Tang, C1
George, DT1
Phillips, MJ1
Lifshitz, M1
Lionetti, TA1
Spero, DE1
Ghassemzedeh, N1
Doty, L1
Umhau, JC1
Rawlings, RR1
Simon O'Brien, E1
Legastelois, R1
Houchi, H1
Vilpoux, C1
Alaux-Cantin, S1
Pierrefiche, O1
André, E1
Naassila, M1
Hirschtritt, ME1
Pagano, ME1
Christian, KM1
McNamara, NK1
Stansbrey, RJ1
Lingler, J1
Faber, JE1
Demeter, CA1
Bedoya, D1
Findling, RL1
Lê, AD1
Harding, S1
Juzytsch, W1
Fletcher, PJ1
Shaham, Y1
Hurt, RD1
Kaplan, GB1
McRoberts, RL1
Smokler, HJ1
Cornelius, JR8
Clark, DB2
Bukstein, OG2
Kelly, TM1
Salloum, IM8
Wood, DS1
Birmaher, B1
Brown, SA1
Mistler, LA1
Brunette, MF1
Rosenberg, SD1
Vidaver, RM1
Luckoor, R1
Iber, M1
Carlson, JA1
Mazza, J1
Kircher, K1
Tran, TA1
Zalewska-Kaszubska, J1
Górska, D1
Dyr, W1
Czarnecka, E1
Cornelius, MD4
Perel, JM5
Ehler, JG4
Jarrett, PJ3
Levin, RL1
Black, A3
Mann, JJ2
Polles, AG1
Smith, PO1
Finley, PR1
Balon, R1
Naranjo, CA3
Poulos, CX1
Bremner, KE1
Lanctot, KL1
Kranzler, HR3
Burleson, JA2
Korner, P1
Del Boca, FK2
Bohn, MJ1
Brown, J3
Liebowitz, N1
Slywka, S1
Hart, LL1
Thase, ME5
Meert, TF1
Joseph, AP1
Farmer, A1
Kabel, DI1
Petty, F1
Janiri, L1
Gobbi, G1
Mannelli, P1
Pozzi, G1
Serretti, A1
Tempesta, E1
Korner, PF1
Babor, TF1
Khouzam, HR1
Kissmeyer, P1
Gardell, LR1
Whalen, CA1
Chattophadyay, S1
Cavallaro, CA1
Hubbell, CL1
Reid, LD1
Zhou, FC1
McKinzie, DL1
Patel, TD1
Lumeng, L2
Li, TK2
Haskett, RF1
Daley, DC1
Jones-Barlock, A1
Upsher, C1
Anton, RF1
Perkins, KA1
Moss, HB1
Maurel, S2
De Vry, J2
Schreiber, R2
Farren, CK1
O'Malley, SS1
de Beun, R1
Jentzsch, KR1
Knoke, DM1
Pettinati, HM1
Gorelick, DA1
Paredes, A1
Rezvani, AH2
Overstreet, DH2
Janowsky, DS2
Kadlec, KE1
Sanhueza, P1
Woodley-Remus, D1
Sellers, EM1
McBride, WJ1
Murphy, JM1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Effect of Fluoxetine on Measures of Domestic Violence[NCT00011765]Phase 2104 participants (Actual)Interventional2001-02-22Completed
5HT3 Antagonists to Treat Opioid Withdrawal and to Prevent the Progression of Physical Dependence[NCT01549652]133 participants (Actual)Interventional2011-04-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Beck Depression Inventory Score (BDIS) Change From Baseline (Prevention of Opioid Withdrawal)

The Beck Depression Inventory (a 21-item self-report multiple-choice inventory) yields a single summed score between 0 and 63; higher scores indicate more severe depression. Change is from baseline score (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken prior to receiving ondansetron or placebo, at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)

Interventionunits on a scale (Mean)
Prevention of Opioid Withdrawal-0.44

Change in Pain Visual Analog Scale (VAS) From Baseline (Prevention of Opioid Withdrawal)

The VAS is a 0 to 100 millimeter scale where 0 corresponds to no pain and 100 to extreme pain, used by participants to indicated their level of pain over the last two weeks. Change is from baseline score for average level of pain (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken prior to receiving ondansetron or placebo, at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)

Interventionunits on a scale (Mean)
Prevention of Opioid Withdrawal-2.68

Change in Roland-Morris Disability Index (RMDI) From Baseline (Prevention of Opioid Withdrawal)

The Roland-Morris Disability Index is a 24-question instrument used to assess level of disability from lower back pain. Scores range from 0-24 with lower scores corresponding to fewer symptoms. Change is from baseline score (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken prior to receiving ondansetron or placebo, at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)

Interventionunits on a scale (Mean)
Prevention of Opioid Withdrawal-2.59

Beck Depression Inventory Score (BDIS) Change From Baseline (Prevention of Physical Dependence)

The Beck Depression Inventory (a 21-item self-report multiple-choice inventory) yields a single summed score between 0 and 63; higher scores indicate more severe depression. Change is from baseline score (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)

Interventionunits on a scale (Mean)
Change in BDIS (Ondansetron)Change in BDIS (Placebo)
Prevention of Physical Dependence-0.60.2

Change in Objective Opioid Withdrawal Score (OOWS) From Baseline (Prevention of Opioid Withdrawal)

"Originally developed by Handelsman, the Objective Opioid Withdrawal Scale (OOWS) score is a well-characterized measure of opioid withdrawal in humans, calculated as the sum of a 13-item physician assessment documenting physically observable signs of withdrawal, which are rated as present (1) or absent (0) during the observation period. The minimum score of 0 means the patient is not showing any signs of opioid withdrawal. The maximum score of 13 signifies all signs of opioid withdrawal to the largest extent possible.~Immediately prior to ondansetron or placebo administration a baseline OOWS score was taken. 30 minutes later participants received naloxone, then 15 minutes later an OOWS score was taken. If deemed necessary by the clinician, participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an OOWS score was taken. Change from the baseline OOWS score to the score assessed following the last naloxone dose is reported." (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose

Interventionunits on a scale (Mean)
Change in OOWS (Ondansetron)Change in OOWS (Placebo)
Prevention of Opioid Withdrawal3.63.6

Change in Objective Opioid Withdrawal Score From Baseline (Prevention of Physical Dependence)

"Originally developed by Handelsman, the OOWS score is a well-characterized measure of opioid withdrawal in humans, calculated as the sum of a 13-item physician assessment documenting physically observable signs of withdrawal, which are rated as present (1) or absent (0) during the observation period. The maximum score is 13 and suggests the patient is showing all signs of opioid withdrawal to the largest extent possible. The minimum score of 0 suggests the patient is not showing any signs of opioid withdrawal.~Immediately prior to ondansetron or placebo administration a baseline OOWS score was taken. 30 minutes later participants received naloxone, then 15 minutes later an OOWS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an OOWS score was taken. Change from the baseline OOWS score to the score assessed following the last naloxone dose is reported." (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose

Interventionunits on a scale (Mean)
Change in OOWS (Ondansetron)Change in OOWS (Placebo)
Prevention of Physical Dependence4.54.2

Change in Pain Visual Analog Scale (VAS) From Baseline (Prevention of Physical Dependence)

The VAS is a 0 to 100 millimeter scale where 0 corresponds to no pain and 100 to extreme pain, used by participants to indicated their level of pain over the last two weeks. Change is from baseline score for average level of pain (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)

Interventionunits on a scale (Mean)
Change in VAS Score (Ondansetron)Change in VAS Score (Placebo)
Prevention of Physical Dependence-2.9-2.8

Change in Roland-Morris Disability (RMDI) Index From Baseline (Prevention of Physical Dependence)

The Roland-Morris Disability Index is a 24-question instrument used to assess level of disability from lower back pain. Scores range from 0-24 with lower scores corresponding to fewer symptoms. Change is from baseline score (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)

Interventionunits on a scale (Mean)
Change in RMDI (Ondansetron)Change in RMDI (Placebo)
Prevention of Physical Dependence-4.6-2.0

Change in Subjective Opioid Withdrawal Score (SOWS) From Baseline (Prevention of Opioid Withdrawal)

The Subjective Opioid Withdrawal Score (SOWS) score is calculated as the sum of 16 subjective patient-reported symptom scores rated on a scale of 0 to 4 (0=not at all, 4=extremely) based on what subjects were experiencing at the time of testing. A maximum score of 64 would suggest the patient is experiencing the symptoms of withdrawal to the maximum extent possible while the lowest score of 0 would suggest the patient is not experiencing any of the symptoms of withdrawal. Immediately prior to ondansetron or placebo administration a baseline SOWS score was taken. 30 minutes later participants received naloxone, then 15 minutes later an SOWS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an SOWS score was taken. Change from the baseline SOWS score to the score assessed following the last naloxone dose is reported (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose

Interventionunits on a scale (Mean)
Change in SOWS (Ondansetron)Change in SOWS (Placebo)
Prevention of Opioid Withdrawal12.512.2

Change in Subjective Opioid Withdrawal Score From Baseline (Prevention of Physical Dependence)

The SOWS score is composed of 16 subjective symptoms rated on a scale of 0 to 4 (0=not at all, 4=extremely) based on what subjects were experiencing at the time of testing. A maximum score of 64 would suggest the patient is experiencing the symptoms of withdrawal to the maximum extent possible while the lowest score of 0 would suggest the patient is not experiencing any of the symptoms of withdrawal. Immediately prior to ondansetron or placebo administration a baseline SOWS score was taken. 30 minutes later participants received naloxone, then 15 minutes later an SOWS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an SOWS score was taken. Change from the baseline SOWS score to the score assessed following the last naloxone dose is reported (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose

Interventionunits on a scale (Mean)
Change in SOWS (Ondansetron)Change in SOWS (Placebo)
Prevention of Physical Dependence16.412.0

Profile of Mood States (POMS) Change in Score From Baseline (Prevention of Opioid Withdrawal)

Profile of Mood States (POMS) is a 65-question survey of how participants have been feeling over the past week, assessing tension, depression, anger, fatigue, confusion and vigor. Each question is on a 5-point scale: 0 (not at all) to 4 (extremely). Overall score range: 0 to 200 (lower scores corresponding to fewer symptoms), calculated by adding total scores for tension, depression, anger, fatigue and confusing, and subtracting that total score from the total score for vigor. Immediately prior to ondansetron or placebo administration a baseline POMS score was taken. 30 minutes later participants received naloxone, then 15 minutes later a POMS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an POMS score was taken. Change from the baseline POMS score to the score assessed following the last naloxone dose is reported. (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose

Interventionunits on a scale (Mean)
Change in POMS Score (Ondansetron)Change in POMS Score (Placebo)
Prevention of Opioid Withdrawal29.328.3

Profile of Mood States (POMS) Change in Score From Baseline (Prevention of Physical Dependence)

(Profile of Mood States) POMS is a 65-question survey of how participants have been feeling over the past week, assessing tension, depression, anger, fatigue, confusion and vigor. Each question is on a 5-point scale: 0 (not at all) to 4 (extremely). Overall score range: 0 to 200 (lower scores corresponding to fewer symptoms), calculated by adding total scores for tension, depression, anger, fatigue and confusing, and subtracting that total score from the total score for vigor. Immediately prior to ondansetron or placebo administration a baseline POMS score was taken. 30 minutes later participants received naloxone, then 15 minutes later a POMS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an POMS score was taken. Change from the baseline POMS score to the score assessed following the last naloxone dose is reported. (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose

Interventionunits on a scale (Mean)
Change in POMS (Ondansetron)Change in POMS (Placebo)
Prevention of Physical Dependence36.129.2

Reviews

7 reviews available for fluoxetine and Alcoholism

ArticleYear
Pharmacotherapy for alcoholic smokers.
    Alcoholism, clinical and experimental research, 2002, Volume: 26, Issue:12

    Topics: Alcoholism; Animals; Fluoxetine; Humans; Nicotine; Smoking

2002
Acute phase and five-year follow-up study of fluoxetine in adolescents with major depression and a comorbid substance use disorder: a review.
    Addictive behaviors, 2005, Volume: 30, Issue:9

    Topics: Adolescent; Alcohol Drinking; Alcoholism; Antidepressive Agents, Second-Generation; Combined Modalit

2005
Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions.
    The Annals of pharmacotherapy, 1994, Volume: 28, Issue:12

    Topics: 1-Naphthylamine; Alcoholism; Antidepressive Agents; Anxiety Disorders; Clinical Trials as Topic; Dep

1994
Fluoxetine in alcoholism.
    The Annals of pharmacotherapy, 1993, Volume: 27, Issue:9

    Topics: Alcoholism; Animals; Double-Blind Method; Fluoxetine; Humans; Male; Prospective Studies; Rats

1993
Neurobehavioural basis for the pharmacotherapy of alcoholism: current and future directions.
    Alcohol and alcoholism (Oxford, Oxfordshire). Supplement, 1996, Volume: 31, Issue:1

    Topics: Alcoholism; Bromocriptine; Dopamine Agonists; Female; Fluoxetine; Humans; Male; Models, Psychologica

1996
The role of selective serotonin reuptake inhibitors in reducing alcohol consumption.
    The Journal of clinical psychiatry, 2001, Volume: 62 Suppl 20

    Topics: Alcohol Drinking; Alcoholism; Animals; Behavior, Addictive; Behavior, Animal; Citalopram; Clinical T

2001
The use of selective serotonin reuptake inhibitors in treating alcoholic subtypes.
    The Journal of clinical psychiatry, 2001, Volume: 62 Suppl 20

    Topics: Alcoholism; Clinical Trials as Topic; Comorbidity; Depressive Disorder; Drug Administration Schedule

2001

Trials

17 trials available for fluoxetine and Alcoholism

ArticleYear
[Fluvoxamine in the treatment of depressive disorders in alcohol dependence: results of randomized open-label comparative study].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2021, Volume: 121, Issue:12

    Topics: Alcoholism; Citalopram; Depressive Disorder; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Selective

2021
Fluoxetine treatment of alcoholic perpetrators of domestic violence: a 12-week, double-blind, randomized, placebo-controlled intervention study.
    The Journal of clinical psychiatry, 2011, Volume: 72, Issue:1

    Topics: Aggression; Alcoholics Anonymous; Alcoholism; Anger; Cognitive Behavioral Therapy; Combined Modality

2011
Moderators of fluoxetine treatment response for children and adolescents with comorbid depression and substance use disorders.
    Journal of substance abuse treatment, 2012, Volume: 42, Issue:4

    Topics: Adolescent; Alcoholism; Antidepressive Agents, Second-Generation; Child; Chronic Disease; Depressive

2012
Preliminary report: double-blind, placebo-controlled study of fluoxetine in depressed alcoholics.
    Psychopharmacology bulletin, 1995, Volume: 31, Issue:2

    Topics: Adolescent; Adult; Alcohol Drinking; Alcoholism; Depression; Double-Blind Method; Female; Fluoxetine

1995
Fluoxetine attenuates alcohol intake and desire to drink.
    International clinical psychopharmacology, 1994, Volume: 9, Issue:3

    Topics: Adult; Alcohol Drinking; Alcoholism; Appetite; Dose-Response Relationship, Drug; Double-Blind Method

1994
Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics.
    The American journal of psychiatry, 1995, Volume: 152, Issue:3

    Topics: Adult; Alcohol Drinking; Alcoholism; Combined Modality Therapy; Comorbidity; Depressive Disorder; Dr

1995
Fluoxetine trial in suicidal depressed alcoholics.
    Psychopharmacology bulletin, 1993, Volume: 29, Issue:2

    Topics: Adult; Alcoholism; Depressive Disorder; Female; Fluoxetine; Humans; Male; Middle Aged; Psychiatric S

1993
A placebo-controlled, double-blind study of fluoxetine in severe alcohol dependence: adjunctive pharmacotherapy during and after inpatient treatment.
    Alcoholism, clinical and experimental research, 1996, Volume: 20, Issue:4

    Topics: Adult; Aftercare; Alcoholism; Combined Modality Therapy; Double-Blind Method; Fluoxetine; Humans; Ma

1996
Effects of fluoxetine at antidepressant doses on short-term outcome of detoxified alcoholics.
    International clinical psychopharmacology, 1996, Volume: 11, Issue:2

    Topics: Adult; Alcoholism; Double-Blind Method; Ethanol; Female; Fluoxetine; Humans; Italy; Male; Middle Age

1996
Assessment of medication compliance in alcoholics through UV light detection of a riboflavin tracer.
    Alcoholism, clinical and experimental research, 1996, Volume: 20, Issue:8

    Topics: Alcoholism; Anti-Anxiety Agents; Buspirone; Dose-Response Relationship, Drug; Double-Blind Method; F

1996
Fluoxetine treatment seems to reduce the beneficial effects of cognitive-behavioral therapy in type B alcoholics.
    Alcoholism, clinical and experimental research, 1996, Volume: 20, Issue:9

    Topics: Adult; Alcohol Drinking; Alcoholism; Cognitive Behavioral Therapy; Comorbidity; Depressive Disorder;

1996
Double-blind fluoxetine in depressed alcoholic smokers.
    Psychopharmacology bulletin, 1997, Volume: 33, Issue:1

    Topics: Adult; Alcoholism; Antidepressive Agents, Second-Generation; Depressive Disorder; Double-Blind Metho

1997
Fluoxetine in depressed alcoholics. A double-blind, placebo-controlled trial.
    Archives of general psychiatry, 1997, Volume: 54, Issue:8

    Topics: Adult; Alcohol Drinking; Alcoholism; Comorbidity; Depressive Disorder; Diagnosis, Dual (Psychiatry);

1997
Fluoxetine versus placebo in depressed alcoholic cocaine abusers.
    Psychopharmacology bulletin, 1998, Volume: 34, Issue:1

    Topics: Adult; Alcoholism; Antidepressive Agents, Second-Generation; Cocaine; Depressive Disorder; Double-Bl

1998
Fluoxetine versus placebo to decrease the smoking of depressed alcoholic patients.
    Journal of clinical psychopharmacology, 1999, Volume: 19, Issue:2

    Topics: Adult; Alcoholism; Depressive Disorder; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middl

1999
Effect of fluoxetine on alcohol consumption in male alcoholics.
    Alcoholism, clinical and experimental research, 1992, Volume: 16, Issue:2

    Topics: Adult; Alcohol Drinking; Alcoholism; Fluoxetine; Hospitalization; Humans; Male; Middle Aged; Single-

1992
Fluoxetine differentially alters alcohol intake and other consummatory behaviors in problem drinkers.
    Clinical pharmacology and therapeutics, 1990, Volume: 47, Issue:4

    Topics: Adult; Alcohol Drinking; Alcoholism; Analysis of Variance; Appetite; Body Weight; Drinking Behavior;

1990

Other Studies

27 other studies available for fluoxetine and Alcoholism

ArticleYear
Impact of CYP2D6 Polymorphism on Equilibrium Concentration of Fluoxetine in Patients Diagnosed With Major Depressive Disorder and Comorbid Alcohol Use Disorders.
    Journal of psychiatric practice, 2021, 09-16, Volume: 27, Issue:5

    Topics: Adult; Alcoholism; Cytochrome P-450 CYP2D6; Depressive Disorder, Major; Fluoxetine; Humans; Middle A

2021
Bupropion, a possible antidepressant without negative effects on alcohol relapse.
    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2019, Volume: 29, Issue:6

    Topics: Alcohol Drinking; Alcoholism; Animals; Antidepressive Agents, Second-Generation; Bupropion; Dopamine

2019
Cessation of fluoxetine treatment increases alcohol seeking during relapse and dysregulates endocannabinoid and glutamatergic signaling in the central amygdala.
    Addiction biology, 2020, Volume: 25, Issue:5

    Topics: Alcoholism; Animals; Central Amygdaloid Nucleus; Disease Models, Animal; Drug-Seeking Behavior; Endo

2020
Evaluation of the antidepressant, anxiolytic and memory-improving efficacy of aripiprazole and fluoxetine in ethanol-treated rats.
    Drug and chemical toxicology, 2014, Volume: 37, Issue:3

    Topics: Alcoholism; Animals; Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Aripiprazole;

2014
Evaluation of antidepressant and memory-improving efficacy of aripiprazole and fluoxetine in alcohol-preferring rats.
    Acta neuropsychiatrica, 2014, Volume: 26, Issue:2

    Topics: Alcoholism; Animals; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Fluoxetine; Male; Pi

2014
[Buccolingual dyskinesia with justified hallucinations].
    Revista de neurologia, 2014, Nov-16, Volume: 59, Issue:10

    Topics: Alcoholism; Benzodiazepines; Clonazepam; Depressive Disorder; Dibenzothiazepines; Disulfiram; Female

2014
Fluoxetine might alleviate brain damage and hypercortisolemia related to chronic alcohol in rats.
    Journal of studies on alcohol and drugs, 2010, Volume: 71, Issue:2

    Topics: Alcoholism; Animals; Cerebral Cortex; Fluoxetine; Hydrocortisone; Male; Neurons; Rats; Rats, Wistar;

2010
Fluoxetine, desipramine, and the dual antidepressant milnacipran reduce alcohol self-administration and/or relapse in dependent rats.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2011, Volume: 36, Issue:7

    Topics: Alcoholism; Analysis of Variance; Animals; Antidepressive Agents; Central Nervous System Depressants

2011
The role of corticotropin-releasing factor in the median raphe nucleus in relapse to alcohol.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2002, Sep-15, Volume: 22, Issue:18

    Topics: Alcoholism; Animals; Behavior, Animal; Choice Behavior; Corticotropin-Releasing Hormone; Disease Mod

2002
Baclofen as adjunctive treatment for a patient with cocaine dependence and schizoaffective disorder.
    Journal of clinical psychopharmacology, 2004, Volume: 24, Issue:5

    Topics: Alcoholism; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Baclofen; Bipolar Disord

2004
Fluoxetine in adolescents with comorbid major depression and an alcohol use disorder: a 3-year follow-up study.
    Addictive behaviors, 2005, Volume: 30, Issue:4

    Topics: Adolescent; Alcoholism; Combined Modality Therapy; Comorbidity; Depression; Diagnosis, Dual (Psychia

2005
Case report of 3 patients with severe mental illness and chronic hepatitis C virus infection treated with interferon-alpha.
    International journal of psychiatry in medicine, 2006, Volume: 36, Issue:4

    Topics: Adult; Alcoholics Anonymous; Alcoholism; Anticonvulsants; Antidepressive Agents, Second-Generation;

2006
Otophyma: a case report and review of the literature of lymphedema (elephantiasis) of the ear.
    The American Journal of dermatopathology, 2008, Volume: 30, Issue:1

    Topics: Adrenal Cortex Hormones; Alcoholism; Anti-Infective Agents; Anti-Inflammatory Agents; Antidepressive

2008
Lack of changes in beta-endorphin plasma levels after repeated treatment with fluoxetine: possible implications for the treatment of alcoholism--a pilot study.
    Die Pharmazie, 2008, Volume: 63, Issue:4

    Topics: Alcoholism; Animals; Antidepressive Agents, Second-Generation; beta-Endorphin; Female; Fluoxetine; H

2008
Treatment of coexisting substance dependence and posttramatic stress disorder.
    Psychiatric services (Washington, D.C.), 1995, Volume: 46, Issue:7

    Topics: Adult; Alcoholism; Behavior Therapy; Combined Modality Therapy; Comorbidity; Fluoxetine; Humans; Ill

1995
Fluoxetine for cocaine dependence in methadone maintenance.
    Journal of clinical psychopharmacology, 1994, Volume: 14, Issue:5

    Topics: Alcoholism; Cocaine; Dopamine Uptake Inhibitors; Drug Synergism; Fluoxetine; Heroin Dependence; Huma

1994
Effects of various serotonergic agents on alcohol intake and alcohol preference in Wistar rats selected at two different levels of alcohol preference.
    Alcohol and alcoholism (Oxford, Oxfordshire), 1993, Volume: 28, Issue:2

    Topics: Alcohol Drinking; Alcoholism; Animals; Buspirone; Chlordiazepoxide; Citalopram; Dose-Response Relati

1993
An unusual case of central pontine myelinolysis.
    Alcohol and alcoholism (Oxford, Oxfordshire), 1995, Volume: 30, Issue:4

    Topics: Alcoholism; Antidepressive Agents; Brain Diseases; Depressive Disorder; Fluoxetine; Humans; Hyponatr

1995
Antidepressant treatment, posttraumatic stress disorder, survivor guilt, and spiritual awakening.
    Journal of traumatic stress, 1997, Volume: 10, Issue:4

    Topics: Alcoholism; Antidepressive Agents, Second-Generation; Awareness; Combat Disorders; Combined Modality

1997
Combination of naltrexone and fluoxetine on rats' propensity to take alcoholic beverage.
    Alcoholism, clinical and experimental research, 1997, Volume: 21, Issue:8

    Topics: Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; Dose-Response Relationship, Drug; Drug Sy

1997
Additive reduction of alcohol drinking by 5-HT1A antagonist WAY 100635 and serotonin uptake blocker fluoxetine in alcohol-preferring P rats.
    Alcoholism, clinical and experimental research, 1998, Volume: 22, Issue:1

    Topics: Alcohol Drinking; Alcoholism; Animals; Dose-Response Relationship, Drug; Drug Synergism; Female; Flu

1998
Comparison of the effects of the selective serotonin-reuptake inhibitors fluoxetine, paroxetine, citalopram and fluvoxamine in alcohol-preferring cAA rats.
    Alcohol (Fayetteville, N.Y.), 1999, Volume: 17, Issue:3

    Topics: Alcohol Drinking; Alcoholism; Animals; Citalopram; Disease Models, Animal; Eating; Ethanol; Female;

1999
Occurrence and management of depression in the context of naltrexone treatment of alcoholism.
    The American journal of psychiatry, 1999, Volume: 156, Issue:8

    Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Comorbidity; Depressive Disorder; Dia

1999
Comparison of hypericum extracts with imipramine and fluoxetine in animal models of depression and alcoholism.
    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 1999, Volume: 9, Issue:6

    Topics: Alcoholism; Animals; Antidepressive Agents; Depression; Drug Evaluation, Preclinical; Female; Fluoxe

1999
Drug-induced reductions in ethanol intake in alcohol preferring and Fawn-Hooded rats.
    Alcohol and alcoholism (Oxford, Oxfordshire). Supplement, 1991, Volume: 1

    Topics: Alcohol Drinking; Alcoholism; Animals; Buspirone; Drinking Behavior; Ethanol; Feeding Behavior; Fluo

1991
Genetic serotonin deficiency and alcohol preference in the fawn hooded rats.
    Alcohol and alcoholism (Oxford, Oxfordshire), 1990, Volume: 25, Issue:5

    Topics: Alcohol Drinking; Alcoholism; Animals; Brain; Fluoxetine; Rats; Rats, Inbred Strains; Receptors, Ser

1990
Effects of Ro 15-4513, fluoxetine and desipramine on the intake of ethanol, water and food by the alcohol-preferring (P) and -nonpreferring (NP) lines of rats.
    Pharmacology, biochemistry, and behavior, 1988, Volume: 30, Issue:4

    Topics: Alcohol Drinking; Alcoholism; Animals; Azides; Benzodiazepines; Desipramine; Drinking Behavior; Feed

1988